p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
Volume and Dose De-Intensified Radiotherapy for p16+ Squamous Cell Carcinoma of the Oropharynx: A Multi-Centre, Single Arm Prospective Cohort Study
Eligibility criteria
Qualifiers
Age 18 or older
Provide informed consent
ECOG performance status 0-2
Histologically confirmed squamous cell carcinoma
Disqualifiers
- Clinical, radiologic or pathologic Ib nodal involvement (including invasion into submandibular gland)
Primary cancer with extension and involvement of the oral cavity
Metastatic disease
Contraindications to radiotherapy or chemotherapy
Trial design
Treatments tested in this trial
- De-intensified chemoradiotherapy
Treatment groups
32 Participants
are divided into 1 treatment groupSponsors and collaborators
AHS Cancer Control Alberta
Lead sponsor
Tom Baker Cancer Centre
Collaborator
Cross Cancer Institute
Collaborator
Source ClinicalTrials.gov